Wuxi Biologics (Cayman) EBIT

The latest EBIT for WXXWY is $13B as of June 2026. That compares with $7.6B in the prior-year period — up 76.3% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Wuxi Biologics (Cayman)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, WXXWY's EBIT moved from $7.6B to $13B — a 76.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Wuxi Biologics (Cayman)'s operating scale or balance-sheet position.

Against Healthcare companies, WXXWY currently prints $13B for EBIT, while the sector average sits near $23B. That is roughly 42.0% below the sector mean. Large gaps often invite a closer look at Wuxi Biologics (Cayman)'s growth, margins, and balance sheet.

A EBIT figure of $13B for WXXWY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting WXXWY's EBIT ($13B), review year-over-year change from $7.6B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.